JP2021522335A5 - - Google Patents

Info

Publication number
JP2021522335A5
JP2021522335A5 JP2021508055A JP2021508055A JP2021522335A5 JP 2021522335 A5 JP2021522335 A5 JP 2021522335A5 JP 2021508055 A JP2021508055 A JP 2021508055A JP 2021508055 A JP2021508055 A JP 2021508055A JP 2021522335 A5 JP2021522335 A5 JP 2021522335A5
Authority
JP
Japan
Prior art keywords
compound
crystalline form
crystal
pattern shown
angles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021508055A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021522335A (ja
JP7406691B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2019/084822 external-priority patent/WO2019206336A1/zh
Publication of JP2021522335A publication Critical patent/JP2021522335A/ja
Publication of JP2021522335A5 publication Critical patent/JP2021522335A5/ja
Application granted granted Critical
Publication of JP7406691B2 publication Critical patent/JP7406691B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021508055A 2018-04-28 2019-04-28 トリアゾロピリミジン系化合物の結晶形、塩のタイプおよびその調製方法 Active JP7406691B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201810399876 2018-04-28
CN201810399876.6 2018-04-28
PCT/CN2019/084822 WO2019206336A1 (zh) 2018-04-28 2019-04-28 一种三唑并嘧啶类化合物的晶型、盐型及其制备方法

Publications (3)

Publication Number Publication Date
JP2021522335A JP2021522335A (ja) 2021-08-30
JP2021522335A5 true JP2021522335A5 (https=) 2022-05-06
JP7406691B2 JP7406691B2 (ja) 2023-12-28

Family

ID=68294924

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021508055A Active JP7406691B2 (ja) 2018-04-28 2019-04-28 トリアゾロピリミジン系化合物の結晶形、塩のタイプおよびその調製方法

Country Status (9)

Country Link
US (1) US11649239B2 (https=)
EP (1) EP3766884B1 (https=)
JP (1) JP7406691B2 (https=)
CN (1) CN112105617B (https=)
DK (1) DK3766884T3 (https=)
ES (1) ES2908424T3 (https=)
PL (1) PL3766884T3 (https=)
PT (1) PT3766884T (https=)
WO (1) WO2019206336A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3766884T3 (pl) * 2018-04-28 2022-07-18 Medshine Discovery Inc. Postać krystaliczna i rodzaj soli związku triazolopirymidynowego oraz sposób jej wytwarzania
AR116315A1 (es) * 2018-09-12 2021-04-21 Dizal Jiangsu Pharmaceutical Co Ltd Compuestos de triazolo-pirimidina y usos de los mismos
US12414952B2 (en) 2018-11-20 2025-09-16 Merck Sharp & Dohme Llc Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use
PE20230372A1 (es) * 2019-08-26 2023-03-06 Incyte Corp Triazolopirimidinas como inhibidores de a2a/a2b
CN120022278A (zh) * 2023-11-22 2025-05-23 英诺湖医药(杭州)有限公司 用于治疗癌症的化合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69820866T2 (de) 1997-03-24 2004-12-30 Kyowa Hakko Kogyo Co., Ltd. [1,2,4]TRIAZOLO[1,5-c]PYRIMIDIN-DERIVATE
AR038366A1 (es) 2001-11-30 2005-01-12 Schering Corp Compuestos de 1,2,4-triazolo [1,5-c] pirimidinas sustituidas, antagonistas del receptor de adenosina a2a, composiciones farmaceuticas, el uso de dichos compuestos para la manufactura de un medicamento para el tratamiento de enfermedades del sistema nervioso central y un kit que comprende combinacion
WO2004029056A1 (ja) 2002-09-24 2004-04-08 Kyowa Hakko Kogyo Co., Ltd. [1,2,4]トリアゾロ[1,5−c]ピリミジン誘導体
PL3611174T3 (pl) * 2017-04-07 2022-08-08 Medshine Discovery Inc. Pochodne [1,2,4]triazolo[1,5-c]pirymidyny jako inhibitor receptora a2a
PL3766884T3 (pl) * 2018-04-28 2022-07-18 Medshine Discovery Inc. Postać krystaliczna i rodzaj soli związku triazolopirymidynowego oraz sposób jej wytwarzania

Similar Documents

Publication Publication Date Title
JP2021522335A5 (https=)
US20240317687A1 (en) Salt of omecamtiv mecarbil and process for preparing salt
JP6439050B2 (ja) Ask1阻害剤を調製するプロセス
RU2497820C2 (ru) Кристаллические формы и две сольватные формы солей молочной кислоты 4-амино-5-фтор-3-[5-(4-метилпиперазин-1-ил)-1 - н-бензимидазол-2-ил]хинолин-2(1н)она
JP2021535207A (ja) 甲状腺ホルモン受容体ベータアゴニスト化合物
KR102142796B1 (ko) 피리디닐아미노피리미딘 유도체의 염, 그의 제조 방법, 및 그의 용도
JP2002522541A (ja) ホスホジエステラーゼ4阻害剤としての置換1,8−ナフチリジン−4(1h)−オン
JP6894917B2 (ja) ピリジニルアミノピリミジン誘導体のメシル酸塩の結晶形、その製造方法及びその使用
CN112088155A (zh) 用于制备2-[[5-(3-氯苯基)-3-羟基吡啶-2-羰基]氨基]乙酸的方法
JP2017521398A (ja) 多環式カルバモイルピリドン化合物の合成
JP2018501289A (ja) ネラチニブマレイン酸塩の新規な結晶形及びその製造方法
JPH0768264B2 (ja) エリスロマイシン誘導体およびその製造法
JP6779972B2 (ja) 呼吸器合胞体ウイルス(rsv)感染症の処置のためのn−[(3−アミノ−3−オキセタニル)メチル]−2−(2,3−ジヒドロ−1,1−ジオキシド−1,4−ベンゾチアゼピン−4(5h)−イル)−6−メチル−4−キナゾリンアミンの結晶形
EP3766884B1 (en) Crystal form and salt type of triazolopyrimidine compound and preparation method therefor
WO2016011195A1 (en) Th-302 solid forms and methods related thereto
CN106045892B (zh) 赛洛多辛及其中间体的新制备方法
DD220308A5 (de) Verfahren zur herstellung von n(piperidinylalkyl)-carboxamiden
CN101778836A (zh) 在1,2-取代的3,4-二氧-1-环丁烯化合物中控制的晶体大小的方法
CN111825700A (zh) 一种吡嗪并噻唑类化合物、其应用及含其的药物组合物
JP2024523506A5 (https=)
KR102124449B1 (ko) 7H-피롤로[2,3-d]피리미딘 화합물을 제조하기 위한 방법
WO2011072383A1 (en) Processes for the purification of lubiprostone
JP2004530706A (ja) 純粋な結晶形態にある5−クロロ−3−(4−メタンスルホニルフェニル)−6’−メチル−[2,3’]ビピリジニル及び合成方法
EP2536705A1 (en) Polymorphic forms of lubiprostone
JPS6116272B2 (https=)